News | December 10, 2025
Zydus launches affordable biosimilar 'Zyrifa' for cancer-related bone complications
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
The study met its primary endpoint and all 11 secondary efficacy endpoints
Captured microbes are then neutralized on engineered microbicidal surfaces
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Subscribe To Our Newsletter & Stay Updated
